The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 31-42

  Zhang, Chuanbo ^a   Kallakury, Bhaskar V ^a   Ross, Jeffrey S ^b   Mewani, Rajshree R ^a   Sheehan, Christine E ^b   Sakabe, Isamu ^a   Luta, George ^a   Kumar, Deepak ^a   Yadavalli, Sivaramakrishna ^a   Starr, Joshua ^c   Sreenath, Taduru L ^d   Srivastava, Shiv ^d   Pollard, Harvey B ^c   Eidelman, Ofer ^c   Srivastava, Meera ^c   Kasid, Usha N ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

KPNA2; prognosis; prostate cancer; therapy response; TNFAIP8

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOCETAXEL; INTEGRIN; KARYOPHERIN ALPHA; MATRIX METALLOPROTEINASE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA INDUCIBLE PROTEIN 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG TARGETING; EXPERIMENTAL MOUSE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TNFAIP8 GENE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASM GRADING; OLIGONUCLEOTIDES, ANTISENSE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RADIOTHERAPY, ADJUVANT; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84876674956     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27996     Document Type: Article

References (43)

1. Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Smith MR,. Effective treatment for early-stage prostate cancer-possible, necessary, or both? N Engl J Med 2011; 364: 1770-72.
3. Kumar D, Whiteside TL, Kasid U,. Identification of a novel tumor necrosis factor-α-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1β- converting enzyme-inhibitory protein. J Biol Chem 2000; 275: 2973-78.
4. Horrevotes AJG, Fontijn RD, Van Zonneveld AJ, et al. Vascular endothelial genes that are responsive to tumor necrosis factor-α in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 1999; 93: 3418-31.
5. You Z, Ouyang H, Lopatin D, et al. Nuclear factor-κB-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 2001; 276: 26398-404.
6. Kumar D, Gokhale P, Broustas C, et al. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorgenicity of MDA-MB435 cells. Oncogene 2004; 23: 612-16.
7. Zhang C, Chakravarty D, Sakabe I, et al. Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1 and MMP-9 expression. Mol Ther 2006; 13: 947-55.
8. Patel S, Wang FH, Whiteside TL, et al. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol 1997; 33: 197-203.
9. Wang Y, Yu Q, Cho AH, et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005; 7: 748-60.
10. Zhang Y, Wang MY, He J, et al. Tumor necrosis factor-α induced protein 8 polymorphism and risk of Non-Hodgkin's lymphoma in a chinese population: a case-control study. PLoS One 2012; 7: e37846.
11. Cutress ML, Whitaker HC, Mills IG, et al. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121: 957-68.
12. Mortezavi A, Hermanns T, Seifert HH, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2011; 17: 1111-21.
13. Roberts TL, Sweet MJ, Hume DA, et al. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 2005; 174: 605-608.
14. Roberts TL, Dunn JA, Terry TD, et al. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 2005; 175: 3569-76.
15. Gokhale PC, Zhang C, Newsome J, et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome (LErafAON). Clin Cancer Res 2002; 8: 3611-21.
16. Zhang C, Newsome JT, Mewani R, et al. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol 2009; 480: 65-83.
17. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-62.
18. Ross JR, Kallakury BVS, Sheehan CE, et al. Expression of nuclear factor-κB and IκBα proteins in proteins in prostatic adenocarcinomas: correlation of nuclear factor-κB immunoreactivity with disease recurrence. Clin Cancer Res 2004; 10: 2466-72.
19. Sheehan GM, Kallakury BV, Sheehan CE, et al. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007; 38: 564-69.
20. Srivastava M, Eidelman O, Jozwik C, et al. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 2006; 87: 303-10.
21. Jozwik CE, Pollard HB, Srivastava M, et al. Antibody microarrays: analysis of cystic fibrosis. Methods Mol Biol 2012; 23: 179-200.
22. Attar RM, Takimoto CH, Gottardis MM,. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009; 15: 3251-55.
23. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85.
24. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022-29.
25. Bonfil RD, Dong Z, Trindade Filho JC, et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase. A pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007; 170: 1-12.
26. Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005; 166: 1173-86.
27. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
28. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48.
29. Upadyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostate intraepithelial neoplasis. Clin Cancer Res 1999; 5: 4105-10.
30. Zeng Y, Openskin K, Goad J, et al. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 2006: 66: 9566-75.
31. Sweeney P, Karashima T, Kim SJ, et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714-24.
32. Sturge J, Caley MP, Waxman J,. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8: 357-68.
33. George DJ, Kantoff PW, Lin DW,. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol 2011; 9: 1-15.
34. George D, Moul JW,. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate 2012; 72: 338-49.
35. Li ZG, Mathew P, Yang J, et al. Androgen receptor-negative prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008; 118: 2697-710.
36. Wan X, Liu J, Lu J-F, et al. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 2012; 18: 726-36.
37. Goodchild J,. Therapeutic oligonucleotides. Methods Mol Biol 2011; 764: 1-15.
38. Davidson BL, McCray PB Jr,. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011; 12: 329-40.
39. Nishinaka Y, Masutani H, Oka S, et al. Importin alpha1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D(3)-up-regulated protein 1. J Biol Chem 2004; 279: 37559-65.
40. Liu H, Li X, Xu Q, et al. Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer. Biochim Biophys Acta 2012; 1826: 112-20.
41. Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 1996; 85: 1113-24.
42. Bacac M, Provero P, Mayran N, et al. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One 2006; 1: e32.
43. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.